

## Review article: prebiotics in the gastrointestinal tract

S. MACFARLANE, G. T. MACFARLANE & J. H. CUMMINGS

---

Dundee University Gut Group, Division of Pathology and Neuroscience, Ninewells Hospital and Medical School, Dundee, UK

Correspondence to:  
Dr S. Macfarlane, Dundee University Gut Group, Division of Pathology and Neuroscience, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK.  
E-mail: s.macfarlane@dundee.ac.uk

---

### Publication data

Submitted 2 May 2006  
First decision 4 June 2006  
Resubmitted 15 June 2006  
Accepted 24 June 2006

---

### SUMMARY

#### Background

Prebiotics are short-chain carbohydrates that alter the composition, or metabolism, of the gut microbiota in a beneficial manner. It is therefore expected that prebiotics will improve health in a way similar to probiotics, whilst at the same time being cheaper, and carrying less risk and being easier to incorporate into the diet than probiotics.

#### Aim

To review published evidence for prebiotic effects on gut function and human health.

#### Methods

We searched the Science Citation Index with the terms prebiotic, microbiota, gut bacteria, large intestine, mucosa, bowel habit, constipation, diarrhoea, inflammatory bowel disease, Crohn's disease, ulcerative colitis, pouchitis, calcium and cancer, focussing principally on studies in humans and reports in the English language. Search of the Cochrane Library did not identify any clinical study or meta-analysis on this topic.

#### Results

Three prebiotics, oligofructose, galacto-oligosaccharides and lactulose, clearly alter the balance of the large bowel microbiota by increasing bifidobacteria and *Lactobacillus* numbers. These carbohydrates are fermented and give rise to short-chain fatty acid and intestinal gas; however, effects on bowel habit are relatively small. Randomized-controlled trials of their effect in a clinical context are few, although animal studies show anti-inflammatory effects in inflammatory bowel disease, while calcium absorption is increased.

#### Conclusions

It is still early days for prebiotics, but they offer the potential to modify the gut microbial balance in such a way as to bring direct health benefits cheaply and safely.

*Aliment Pharmacol Ther* 24, 701–714

## DEFINITION

'A prebiotic is a non-digestible food ingredient that beneficially affects the host by selectively stimulating the growth and/or activity of one of a limited number of bacteria in the colon, and thus improves host health'.<sup>1</sup> Prebiotics are important because of: (i) the growing belief that there is such a thing as a healthy or balanced gut microbiota, (ii) the demonstration that prebiotics can alter the composition of the microbiota towards this more healthy profile, (iii) as an alternative to probiotics, which can be difficult to handle in some foodstuffs, but whose benefits to health in terms of diarrhoea prevention and immunomodulation are becoming increasingly well established and (iv) because prebiotics currently in use, especially inulin and its derivatives, and galacto-oligosaccharides (GOS) are relatively cheap to manufacture or extract from plant sources, and in addition to having beneficial effects on the gut microbiota and host, they are also valuable functional ingredients in foods with the potential to give fat-based spreads and dairy products improved organoleptic properties.

Gibson *et al.*<sup>2</sup> recently reviewed their original prebiotic concept in the light of research published over the past 10 years, particularly the three key aspects of the original definition: (i) resistance to digestion, (ii) fermentation by the large intestinal microbiota and (iii) a selective effect on the microbiota that has associated health-promoting effects. They now propose that 'A prebiotic is a selectively fermented ingredient that

allows specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health'. The key ideas in both this and the earlier definition are 'selective' and 'benefit/improve... host... health'.

The main candidates for prebiotic status are shown in Table 1.

## SELECTIVE MODIFICATION OF THE GUT MICROBIOTA

Inulin, fructo-oligosaccharides (FOS), trans-GOSs and lactulose, when taken in the diet in relatively small amounts (5–20 g/day) have been clearly shown in human studies to stimulate growth of health-promoting species belonging to the genera *Bifidobacterium* and *Lactobacillus*, which ordinarily, are not the most numerous organisms in the gut except in the breast-fed baby.<sup>2, 3</sup> This change in the microbiota was initially observed by Japanese researchers and reported in the first issue of a new journal, *Bifidobacteria and Microflora* in March 1982. However, their effects on the global composition of the flora is less well documented at the present time because newly developed molecular methods for identification of individual species are only now demonstrating its true complexity and diversity.

Almost any carbohydrate that reaches the large bowel will provide a substrate for the commensal microbiota, and will affect its growth and metabolic activities. This has been shown for non-starch polysac-

**Table 1.** Properties of common non-digestible oligosaccharides

Name	Composition	Method of manufacture	DP
Inulin	$\beta(2-1)$ fructans	Extraction from chicory root	11–65
Fructo-oligosaccharides	$\beta(2-1)$ fructans	Tranfructosylation from sucrose, or hydrolysis of chicory inulin	2–10 3–5
Galacto-oligosaccharides	Oligo-galactose (85%), with some glucose and lactose	Produced from lactose by $\beta$ -galactosidase	2–5
Soya-oligosaccharides	Mixture of raffinose (F-Gal-G) and stachyose (F-Gal-Gal-G)	Extracted from soya bean whey	3–4
Xylo-oligosaccharides	$\beta(1-4)$ -linked xylose	Enzymic hydrolysis of xylan	2–4
Pyrodextrins	Mixture of glucose-containing oligosaccharides	Pyrolysis of potato or maize starch	Various
Isomalto-oligosaccharides	$\alpha(1-4)$ glucose and branched $\alpha(1-6)$ glucose	Transgalactosylation of maltose	2–8

DP, degree of polymerization; F, fructose; Gal, galactose; G, glucose.

charides (NSP; dietary fibre),<sup>4</sup> and will occur with other substrates, such as resistant starches, sugar alcohols and lactose. However, stimulation of growth by these carbohydrates is a non-specific, generalized effect, which probably involves many of the major saccharolytic groups, and associated cross-feeding species in the large bowel.<sup>5</sup> The selective properties of prebiotics are supposed to relate to the growth of bifidobacteria and lactobacilli at the expense of other groups of bacteria in the gut, such as *Bacteroides*, clostridia, eubacteria, enterobacteria, enterococci, etc. In practice, studies show that such selectivity is variable, and the extent to which changes in the microbiota allow a substance to be called prebiotic have not been established, although this may have to be underwritten in the near future for food labelling and health claims legislation purposes. For example, wide variations are evident in the ratios of bifidobacteria to *Bacteroides* in normal faeces, from around 0.08 to 1.07, and an equally wide range in microbial growth responses occurs in human volunteers following prebiotic consumption, with final ratios of these organisms being from 0.40 to 5.01.<sup>6</sup>

Not only has 'selectivity' not been defined in quantitative terms, but also there are qualitative aspects of the microbiota that also need to be reviewed in this context. Thus, some investigations have shown increases in other bacterial genera, such as *Roseburia*, *Ruminococcus* and *Eubacterium*, with established prebiotics-like inulin.<sup>7, 8</sup> Do such a changes negate the concept of selectivity? Moreover, it is now recognized that many bacteria inhabiting the large bowel have not yet been identified and are difficult to culture routinely.<sup>9</sup> One consequence of this is that we do not know what the global effects of prebiotics are on the structure of the microbiota. Another important factor to bear in mind when using prebiotics to selectively modify the composition of the microbiota is that prebiotics on their own can only enhance the growth of bacteria that are already present in the gut. However, different people harbour different bacterial species, while the composition of the microbiota can be affected by a variety of other factors, such as diet, disease, drugs, antibiotics, age, etc.

## A HEALTHY MICROBIOTA

A healthy, or 'balanced' microbiota has been considered to be one that is predominantly saccharolytic and comprises significant numbers of bifidobacteria and

lactobacilli.<sup>10</sup> This concept is based on a number of observations. The genera *Bifidobacterium* and *Lactobacillus* do not contain any known pathogens, and they are primarily carbohydrate-fermenting bacteria, unlike other groups, such as *Bacteroides* and clostridia which are also proteolytic and amino acid fermenting. The products of carbohydrate fermentation, principally short-chain fatty acids (SCFA) are beneficial to host health, while those of protein breakdown and amino acid fermentation, which include ammonia, phenols, indoles, thiols, amines and sulphides are not.<sup>11</sup> Furthermore, lactic acid-producing bacteria, such as bifidobacteria and lactobacilli are believed to play a significant role in the maintenance of colonization resistance, through a variety of mechanisms.<sup>12</sup> Equally importantly, the exclusively breast-fed neonate has a microbiota containing proportionately higher numbers of bifidobacteria, which is believed to be part of the baby's defence against pathogenic micro-organisms, and which may be important primers for their immune system. This microbiota is nurtured by oligosaccharides in breast milk, which can be considered to be the original prebiotics.

While some investigations have reported detailed analysis of the effects of prebiotics on microbial communities in the gut,<sup>13</sup> to date, the majority of microbiological studies carried out on prebiotics have only characterized bacterial populations to group or genus level. Because of this, an important issue is seldom addressed, namely that which relates to the types of bifidobacteria and lactobacilli that ferment, or are affected by prebiotics in the gut. Not all of these organisms are able to utilize or compete for prebiotics,<sup>13</sup> or have any recognized health-promoting properties, therefore unless it is known which species are being stimulated by these substances, we cannot say for certain that specific health benefits will necessarily accrue from prebiotic consumption. This argument applies equally to the lack of knowledge of the effect of prebiotics on the many newly discovered, unculturable, species belonging to other genera, whose effects on health are presently unknown and which prebiotics may affect.

## MUCOSAL MICROBIOTAS

Most studies on the colonic microbiota have focused on faecal material. However, increasing evidence suggests that the epithelial surface is also heavily colonized by large and diverse bacterial communities, which are structurally distinct from those that occur in the

Bacteria	Log <sub>10</sub> bacterial number/g of mucosal tissue			
	Proximal gut		Distal gut	
	Control	With prebiotic	Control	With prebiotic
Total anaerobes	8.5 ± 0.2	8.6 ± 0.2	8.7 ± 0.1	8.6 ± 0.1
Facultative anaerobes	6.4 ± 0.4	5.9 ± 0.4	6.4 ± 0.3	5.9 ± 0.4
Bifidobacteria	5.3 ± 0.4	6.3 ± 0.3†	5.2 ± 0.3	6.4 ± 0.3†
Eubacteria	4.5 ± 0.3	6.0 ± 0.4†	4.6 ± 0.3	6.1 ± 0.3†
Clostridia	5.1 ± 0.3	4.9 ± 0.3	5.0 ± 0.3	4.9 ± 0.3†
Lactobacilli	3.0 ± 0.1	3.7 ± 0.2†	3.1 ± 0.1	3.6 ± 0.2
<i>Bacteroides</i>	8.1 ± 0.3	8.3 ± 0.2	8.3 ± 0.2	8.5 ± 0.2
Enterobacteria	6.2 ± 0.4	5.6 ± 0.4	6.4 ± 0.3	5.9 ± 0.4

**Table 2.** Effects of dietary supplementation with inulin and oligofructose on mucosal bacterial communities in the large intestine in a human feeding trial\*

\* Results are from Langlands *et al.*<sup>7</sup> Volunteers were fed either a mixture comprising 7.5 g of oligofructose and 7.5 g of inulin per day for 2 weeks ( $N = 14$ ) or not given anything ( $N = 15$ ).

† Shows prebiotic effects that were significantly different from their respective controls ( $P < 0.05$ ).

gut lumen.<sup>14–16</sup> Such bacteria, which grow in biofilms on or adjacent to the colonic mucosa, exist in close proximity to the host and are likely to be particularly important in modulating immune system reactivity.<sup>17, 18</sup> Indeed, studies have shown that mucosal communities can change markedly in inflammatory conditions, such as ulcerative colitis (UC) and Crohn's disease (CD).<sup>16, 19</sup> Importantly, the composition of these mucosal communities in humans can be manipulated through the use of prebiotics. Langlands *et al.*<sup>7</sup> showed that bifidobacterial and eubacterial numbers could be increased more than 10-fold in mucosae of the proximal and distal colons in patients fed 15 g of a prebiotic mixture containing 7.5 g inulin and 7.5 g FOS/day for 2 weeks prior to colonoscopy (Table 2). Potential mechanisms whereby dietary components in the gut lumen can affect bacteria on the mucosal surface are illustrated in Figure 1. Until this study, it was unclear if mucosal communities could sequester dietary components, or whether they were principally dependent on mucus and other host secretions. However, the fact that small additions to the diet can have profound effects on the mucosal microbiota opens up the possibility of developing therapeutic strategies for tackling bacteria-associated gut diseases.

## FERMENTATION

While the concept of selectivity and changing the composition of the colonic microbiota is essential to

the characterization of prebiotics, the suggestion that these substances are characteristically non-digestible but fermentable is probably not. Many dietary carbohydrates and proteins undergo fermentation in the large intestine and thus this cannot be a primary defining quality of prebiotics. Nevertheless, fermentation of carbohydrates is viewed as a beneficial function of the microbiota, and currently recognized prebiotic carbohydrates are probably all fermented. Certainly, faecal recoveries of dietary inulin and oligofructose (OF) have been universally close to zero, and such studies that have been carried out on the upper intestinal digestibility of these substances have suggested recoveries of around 88% at the ileo-caecal junction.<sup>20</sup> Thus, prebiotics will yield SCFA, such as acetate, propionate and butyrate, together with hydrogen, carbon dioxide and biomass, as do other fermented carbohydrates. However, whilst many bacterial species grow well on prebiotic carbohydrates such as low degree of polymerization (DP) fructans, there may be a selective benefit to some types of bifidobacteria and lactobacilli, depending on the sugar composition and molecular size of the prebiotic.<sup>21, 22</sup>

## BOWEL HABIT AND CONSTIPATION

Any carbohydrate that reaches the large bowel should have a laxative effect, whether fermented or not. Table 3 summarizes the results of seven published investigations in which mean daily faecal weight was




Figure 1. Mechanisms whereby dietary substrates become available for mucosa-associated microbiotas in the large intestine.

Table 3. Effects of prebiotics on mean daily stool weight (MDSW)

Type	Amount (g/day)	N	MDSW/g/day		g/g increase	Reference
			Control	Prebiotic		
Oligomate 55 (GOS)	4.8	12	151	134	0	Ito <i>et al.</i> <sup>23</sup>
	9.6	12		151	0	
	19.2	12		162	0.6	
Oligofructose	15.0	8	134	154*	1.3	Gibson <i>et al.</i> <sup>24</sup>
Inulin	15	4	92	123	2.1	Alles <i>et al.</i> <sup>25</sup>
Oligofructose	5	24	272	279	0	
	15			264	0	
TOS	10	8	105	80	0	Bouhnik <i>et al.</i> <sup>26</sup>
Inulin	31	9	129	204*	2.4	Castiglia-Delavaud <i>et al.</i> <sup>27</sup>
Inulin	15	12	129	155	1.7	Van Dokkum <i>et al.</i> <sup>28</sup>
Oligofructose	15	12		108	0	
GOS	15	12		158	1.9	
Isomalt†	30	19	99	111	0.4	Gostner <i>et al.</i> <sup>29</sup>

N, number of subjects; MDSW, mean daily stool weight; g/g increase, gram increase in stool weight per day per gram prebiotic fed; GOS, galacto-oligosaccharides; TOS, transgalacto-oligosaccharide.  
 \* Significantly different from control (P < 0.05).  
 † Proposed as a prebiotic but not established as one.

measured, and the response to a prebiotic determined.<sup>23-29</sup> When the extent of change in bowel habit is normalized to per gram of prebiotic ingested, it can be noted that a significant increase in stool output is seen in only two of the seven studies. This is 1.3 g of

stool/g of prebiotic for OF (134-154 g of stool/day) in the study of Gibson *et al.*<sup>24</sup> and 2.4 g/g for inulin (129-204 g/day) in the study of Castiglia-Delavaud *et al.*<sup>27</sup> Four studies recorded virtually no change at all in bowel habit.



Table 4. Effect of prebiotics on calcium absorption in humans

Subjects	N	Prebiotic	Study design	Absorption method	Result	References
Adolescents M, 14–16 years	12	FOS 15 g	RCT feeding study (9-day periods)	<sup>44</sup> Ca <sup>48</sup> Ca	Fractional absorption increased (48 ± 17–60 ± 17)	van den Heuvel <i>et al.</i> <sup>88</sup>
Adolescents F, 11–14 years	59	FOS 8 g FOS + inulin 8 g	Randomized crossover feeding study (3-week periods)	<sup>46</sup> Ca <sup>42</sup> Ca	FOS effect FOS/inulin absorption increased (32 ± 10–38 ± 10)	Griffin <i>et al.</i> <sup>89</sup>
Adolescents F/M, 9–13 years	100	Mixed long and short-chain inulin 8 g	1 year supplement to diet	<sup>46</sup> Ca	Calcium absorption greater. Bone mineral density higher	Abrams <i>et al.</i> <sup>86</sup>
M, 20–30 years	12	Inulin 15 g FOS 15 g GOS 15 g	Randomized crossover feeding study (21-day periods)	<sup>44</sup> Ca <sup>48</sup> Ca	No effect on calcium or iron absorption	van den Heuvel <i>et al.</i> <sup>87</sup>
M	9	Inulin	Latin square feeding study (28-day periods)	Balance	Significant increase in absorption. No effect on magnesium, iron or zinc	Coudray <i>et al.</i> <sup>90</sup>
Postmenopausal women, 50–70 years	12	FOS 10 g	RCT feeding study (5-week periods)	<sup>44</sup> Ca and balance	No effect	Tahiri <i>et al.</i> <sup>99</sup>
Postmenopausal women, 55–65 years	12	TOS 20 g	RCT crossover (9-day periods)	<sup>44</sup> Ca <sup>48</sup> Ca	Ca absorption increased (21 ± 7–24 ± 7)	van den Heuvel <i>et al.</i> <sup>100</sup>
8 men and 7 women, 25–36 years	15	FOS 0.8–1.1 g	Absorption from fortified milk drinks	<sup>42</sup> Ca <sup>43</sup> Ca <sup>44</sup> Ca	No effect	Lopez-Huertas <i>et al.</i> <sup>101</sup>

At best, therefore, prebiotics are only mildly laxative, as these results compare with an increase of stool output of 5.4 g/g for NSP from wheat and 3.7 g/g for gums and mucilages, such as ispaghula, sterculia, etc.<sup>30</sup> Measuring small changes in mean daily faecal weight is, however, difficult and requires accurate methods by using appropriate faecal markers. Reports of no change in bowel habit with prebiotics may sometimes just be a reflection of the methodology, or a type II statistical error. At this comparatively early stage in the study of prebiotics, it might be noted from Table 3 that inulin appears to be a better laxative than OF. This could be due to its higher molecular weight, and the lower solubility of inulin resulting in its slower fermentation, an argument also made by Van Loo<sup>31</sup> in respect of several properties of these fructans. The laxative properties of inulin have long been known, and were in fact, first reported in 1912 by Lewis.<sup>32</sup>

The studies reported in Table 3 almost all show a clear bifidogenic effect, so this alone is not sufficient to change bowel habit. They also report increased flatulence and bloating in many volunteers, as well as

changes in fermentation patterns. These include an increase in faecal nitrogen, largely due to increased excretion of bacterial cell mass as a result of carbohydrate breakdown, increased faecal energy, lower pH, but no change in SCFA concentrations in faeces, or bile acid profiles.


Studies of prebiotics in the management of constipation have mostly been qualitative, relying on bowel habit diaries, and subjective patient reports of symptoms.<sup>33–35</sup> Den Hond *et al.*<sup>36</sup> did measure stool output in six healthy volunteers with low stool frequency (4.0 ± 0.4 S.E.M. stools/week), and showed a non-significant increase from 91 ± 107 to 113 ± 22 g of stool/day with 15 g of inulin (equivalent to 1.5 g of stool/g of inulin fed), but a significant increase to 6.5 stools/week. Moreover, Chen *et al.*<sup>37, 38</sup> showed significant increases in stool weight from 32.4 ± 1.8 (S.E.M.) to 69.0 ± 3.6 g/day in elderly constipated subjects fed 10 g/day OF. This is somewhat surprising in view of the results in Table 3. Furthermore, a 70% increase in stool output was recorded by these authors in a similar study with isomalto-oligosaccharides. In

this latter investigation, the increase in stool weight was due to increased microbial cell mass, which would be the correct mechanism as isomalto-oligosaccharides are not recovered in faeces.<sup>29</sup> The parallels here with lactulose are clear, but in mechanistic terms, we now know that all of these carbohydrates also change the species composition of the microbiota.<sup>2, 39</sup>

## TRAVELLER'S DIARRHOEA

Traveller's diarrhoea (TD) is an ideal model in which to test the benefits of prebiosis. Despite this, only one clinical study has been published<sup>40</sup> in which 244 healthy subjects travelling to high or medium risk destinations for TD were randomized to receive either 10 g of FOS or placebo for 2 weeks prior to their holiday, and then for the 2 weeks they were away. The prevalence of diarrhoea was less in the FOS group, as recorded in a poststudy questionnaire, at 11.2% FOS vs. 19.5% placebo, but this was not statistically significant ( $P = 0.08$ ). There were no significant differences in the primary end points of bowel frequency or consistency between the two groups, as recorded in bowel habit diaries, but those subjects taking FOS experienced less severe attacks of diarrhoea than the placebo group (Figure 2). These results were strongly indicative of a benefit of prebiotics, but not conclusive. This could be because not all cases of TD are due to infection, and other factors contribute to the condition, including exposure to rarely encountered foods, alcohol excess and anxiety. Moreover, many infecting agents that cause TD, such as *Escherichia coli*, campylobacters, *Salmonella*, giardia and yersinia, mainly affect the small intestine, and the essence of prebiosis is a change in the microbiota of the large bowel.

**Figure 2.** Diarrhoea severity score in travellers ( $N = 244$ ) taking either a placebo or oligofructose 10 g/day for 14 days prior to travel and during the holiday. The figure shows that the severity of episodes of diarrhoea was less with oligofructose shifting the distribution of scores to the left<sup>40</sup> (\*  $P < 0.05$ ).



## Well-being

An unexpected finding from the TD study cited above was the significantly greater proportion of subjects on FOS (12.9% vs. 4.7%,  $P < 0.04$ ) who responded affirmatively to the poststudy questionnaire, by ticking the box that said 'whilst taking the sachets, did you experience a general improvement in well-being'? Well-being is a state of body and mind that is very difficult to define and measure. It is, however, a core principle of the functional food concept that wellness is improved rather than disease or symptoms treated.<sup>10</sup> Food has long been known to induce a sense of well-being, for complex reasons, but little attention has been paid to this key component of quality of life, despite wellness being something to which we all aspire. Well-being is now on the agenda in the EU and an active debate is taking place over whether claims for improved well-being can be made in the context of the new regulation (EC/2005 Regulation of the European Parliament and of the Council on Nutrition and Health Claims Made on Foods). Such claims will be allowed, but as the preamble to the Regulation states 'There are many factors, other than dietary ones, that can influence psychological and behavioural functions. Communication on these functions is thus very complex and it is difficult to convey a comprehensive, truthful and meaningful message in a short claim to be used in the labelling and advertising of foods. Therefore, it is appropriate, when using psychological and behavioural claims, to require scientific substantiation'.

The gut is a key organ in the relationship of food to well-being. Many sensations arise from the gut in association with the intake of food, such as satiety,

postprandial intestinal sensations, bowel habit, gas production and excretion. The boundary between a pleasant feeling and unwanted sensations, such as nausea, bloating, pain, incomplete rectal evacuation, etc. is not well defined, and is the same boundary as between irritable bowel syndrome (IBS) and health. The large gut is well served by the enteric nervous system, and there is a complex interplay between neural and hormonal regulation and our consciousness. Such perception of our digestive processes can be measured to some extent.<sup>41</sup> However, few studies have been undertaken in humans in which the effects of prebiotics on well-being have been investigated. One recently reported study<sup>42</sup> observed the effect of the intake of 10 g/day inulin on aspects of energy, mood and cognitive function in 142 healthy volunteers, as assessed by a battery of questionnaires. Included in this were six questions relating to the gastrointestinal tract. No significant differences were recorded between placebo and inulin periods in mood, bowel function, sleep quality, memory or performance; however, subjects noticed increased wind, bloating and stomach cramps with inulin, and very slight changes in bowel habit.

Clearly, this is an area that deserves more work, especially with objective measures of gastrointestinal function that can be related to changes in brain activity, perhaps employing new imaging technology and reproducible descriptions of well-being using established criteria and questionnaires.

### Irritable bowel syndrome

There are currently no published full papers of randomized-controlled trials (RCT) concerning the use of prebiotics alone in IBS. A number of studies using prebiotics have been carried out with varying benefits<sup>43</sup> but the pathogenesis of IBS may preclude the use of prebiotics in this condition. While it is accepted that IBS is probably not a single syndrome, and may well encapsulate several different pathophysiologies, it is now clear that at least a subset of these patients have increased intestinal gas production,<sup>44, 45</sup> reduced tolerance of gas in the gut<sup>46</sup> and differences in their gut microbiotas.<sup>47</sup> Marked variabilities can be seen in the bacterial composition of faeces from IBS patients by using quantitative polymerase chain reaction (PCR), for example, Malinen *et al.*<sup>47</sup> reported reduced numbers of lactobacilli and bifidobacteria in diarrhoea-predominant IBS. The known abilities of some prebiotics

to selectively increase numbers of lactobacilli and bifidobacteria in both the faecal microbiota and mucosal populations should, in principle, allow correction of these imbalances in microbial community structure.

Bifidobacteria and lactobacilli do not produce gases as end products of metabolism.<sup>48</sup> However, as previously discussed, a well known consequence of feeding even moderate amounts of some of the currently favoured prebiotics is increased gas production in the gut, because of their rapid fermentation in the proximal bowel.<sup>40, 49</sup> This might preclude prebiotic use in diarrhoea-predominant IBS, or where bloating or gas are prominent symptoms, but might allow their mild laxative properties<sup>20</sup> to be useful in constipation-predominant IBS. The only preliminary report so far suggests no benefit, even in mainly constipated patients.<sup>50</sup>

### Antibiotic-associated diarrhoea

Probiotics now have an established place in the prevention of antibiotic-associated diarrhoea (AAD), and so it might be expected that prebiotics would also be effective in some circumstances. Changing the composition of the microbiota to one dominated by bifidobacteria and lactobacilli should, in principle, increase colonization resistance in the gut. Furthermore, many intestinal pathogens utilize monosaccharides or low DP oligosaccharide sequences as receptors, binding to which is the first step in the colonization process.<sup>12</sup> Gibson *et al.*<sup>12</sup> report that there are several pharmaceutical preparations based on these receptor saccharides in clinical trials and suggest they should, by binding to the oligosaccharide receptor on the gut mucosal surface, inhibit adhesion of pathogens and act as 'decoy oligosaccharides'.

*In vitro* modelling of AAD by using clindamycin and *Clostridium difficile* inoculation of human faecal microbiotas<sup>51</sup> showed that supplementing cultures with either FOS, GOS or inulin reduced clostridial numbers and increased total bifidobacteria counts. However, when the cultures were supplemented with clindamycin, marked reductions in bifidobacteria occurred, which were augmented by the presence of prebiotics, while FOS actually enhanced growth of *C. difficile* under these conditions. Although these data suggested that stimulation of bifidobacterial growth by the prebiotics was responsible for suppressing the pathogen, subsequent modelling experiments by using chemostats demonstrated that bifidobacteria did not manifest antimicrobial effects against *C. difficile*, indicating that



other mechanisms must have been involved. These results are supported in human trials.

Three RCT of prebiotics and the prevention of AAD have been reported. Lewis *et al.*<sup>52</sup> undertook a large study involving 435 patients aged over 65 years, who were hospital in-patients prescribed a broad spectrum antibiotic in the 24 h before the study. They were randomized to receive either 12 g of OF daily or placebo, for the duration of the antibiotic treatment, and 1 week beyond. The end points were based on a stool form and defecation frequency diary, and faecal microbiology. Twenty-seven percentage of all patients developed diarrhoea, of which 11% had *C. difficile* toxin-positive stools. Oligofructose made no difference to the risk of diarrhoea, or other aspects of bowel habit, or *C. difficile* infection. Why did the OF not protect these patients from AAD? The amount of OF was sufficient, and compliance was good. Bifidobacterial counts increased in the OF group and decreased in the control group. The authors suggested that in the presence of antibiotic, OF does not show such selectivity in changing the microbiota, and may also have stimulated the growth of other anaerobes.

However, in another RCT, Lewis' group<sup>53</sup> successfully prevented further episodes of diarrhoea in patients with *C. difficile*-associated symptoms who were treated with metronidazole and vancomycin. Again, 12 g of OF was used and given for 30 days. Follow-up was for a further 30 days. FOS significantly reduced episodes of diarrhoea from 34.3% (placebo) to 8.3% (FOS;  $P < 0.001$ ). Hospital length of stay was also reduced and bifidobacterial numbers increased significantly with the prebiotic.

In abstract only, Brunser *et al.*<sup>54</sup> reported a RCT in children aged 1–2 years who were given a mixture of FOS and inulin after 1 week of Amoxicillin therapy for acute bronchitis. A significant increase in faecal bifidobacteria was seen on day 7 of the prebiotic supplement without any apparent change in diarrhoeal symptoms.

The antipathogenic effects of prebiotics have also been investigated in studies other than those associated with AAD. A investigation in 66 liver transplant patients given various probiotics and prebiotics (but no placebo) post-operatively showed no benefit for FOS, but a major reduction in infections, especially urinary infections, with probiotics.<sup>55</sup> Similarly, synbiotic treatment involving OF and a variety of probiotics was found to be ineffective in preventing systemic inflammation and postsurgical septic complications.<sup>56</sup> A synbiotic is a mixture of a probiotic and a prebiotic,

and the rationale for this combination is that the prebiotic is used to stimulate growth of the probiotic in the gut, thereby increasing its effectiveness.

### Inflammatory bowel disease

The enthusiasm with which probiotics have been used in inflammatory bowel disease (IBD)<sup>57, 58</sup> and their apparent benefits has led to the suggestion that prebiotics might also be useful. Certainly, patients would welcome such an approach, which would be inexpensive and without significant side-effects, provided it were effective. Despite this, there are no reports of RCT using prebiotics alone in either UC or CD, although some preliminary work suggests prebiotics have anti-inflammatory properties. Reports of animal studies are quite numerous, and in general, they show a benefit in reducing symptoms, including inflammation, as seen histologically and biochemically, with appropriate increases in bifidobacteria or lactobacilli, and in some reports, in concentrations of butyrate in the gut. These effects are seen across a wide range of models of IBD, and with varying prebiotics, including the trinitrobenzene sulphonic acid (TNBS) rat treated with either FOS<sup>59</sup> or lactulose,<sup>60</sup> the dextran sulphate sodium (DSS) model with inulin,<sup>61</sup> a mixture of inulin/FOS<sup>62</sup> or lactulose<sup>63</sup> and the HLA-B27 transgenic rat, treated again with a mixture of inulin/FOS.<sup>64</sup> There are also multiple reports of the use of 'prebiotic-germinated barley foodstuff' in both animals and humans from one research group<sup>65</sup> but this substance is a mixture of NSP (fibre) and glutamine and has not been accepted as a prebiotic.<sup>2</sup>

In a small open-label trial in humans, 10 patients with active ileo-colonic CD were given 15 g FOS daily for 3 weeks. A significant reduction in the Harvey Bradshaw index of disease activity was observed, and faecal bifidobacteria increased from  $\log_{10}$  8.8 to  $\log_{10}$  9.4 cells per gram dry faeces. The proportion of dendritic cells expressing Toll-like receptors TLR2 and TLR4 also increased.<sup>66</sup>

Furrie *et al.*<sup>18</sup> have reported a double-blinded RCT in which a synbiotic was fed to UC patients for a period of 1 month. Eighteen patients were enrolled in the study, and those receiving the synbiotic were given 12 g of Synergy 1 (OF-enriched inulin) and  $2 \times 10^{11}$  live *Bifidobacterium longum* per day. Results showed that bifidobacterial numbers on the rectal mucosa increased 42-fold in subjects receiving the synbiotic. This was accompanied by highly significant reductions

in mucosal proinflammatory cytokines (TNF- $\alpha$ , IL-1 $\alpha$ ) as well as inducible  $\beta$ -defensins 2, 3 and 4. These substances are antimicrobial peptides produced by epithelial cells during inflammatory episodes in the gut, but unlike TNF- $\alpha$  and IL-1 $\alpha$ ,  $\beta$ -defensins are not formed by inflammatory cells infiltrating the mucosa, so they were important markers of healing events occurring on the epithelial surface. Histology showed marked reductions in inflammatory cells and crypt abscesses in patients receiving the synbiotic, together with regeneration of normal tissue, while sigmoidoscopy scores and clinical activity indices were also improved in these individuals. This short-term pilot study provides the first evidence that synbiotics have the potential to be developed into acceptable therapies for patients suffering from acute UC, but further work is needed to investigate the long-term efficacy of synbiotics in inducing and maintaining remission.

Pouchitis patients do well with probiotics, and one successful study has been reported in which prebiotics were used for this condition.<sup>67</sup> In a randomized double-blind crossover study, 24 patients with stable asymptomatic pouchitis were given 24 g of inulin or placebo daily, for 3 weeks each. At the end of the prebiotic period, results showed that there was a reduction in the endoscopic and histological pouchitis disease activity index (PDAI) score, together with lower gut pH, reductions in faecal *Bacteroides fragilis* and secondary bile acids. Butyrate concentrations were increased, while symptom scores were low initially, and were essentially unchanged.

## CALCIUM ABSORPTION AND BONES

Lactose has long been thought to enhance dietary calcium absorption, although the effect in healthy humans is not shown consistently.<sup>68</sup> The effects of other carbohydrates have been studied including prebiotics derived from lactose, such as GOS. Much of this work has been carried out in animal models, which show clearly enhanced absorption of calcium, and also magnesium and iron with GOS, FOS and inulin.<sup>69–74</sup> More importantly, this enhancement of absorption leads to increased bone mineral density<sup>75</sup> and prevents osteopenia following gastrectomy or ovariectomy.<sup>72, 76, 77</sup> Calcium absorption from the gut is mediated by a vitamin D and energy-dependent carrier-mediated transport process, principally in the duodenum and upper jejunum. However, passive non-saturable paracellular transport also occurs more distally in the gut, which is

probably 1,25(OH)<sub>2</sub>D<sub>3</sub> responsive.<sup>78</sup> In the rat, the caecum plays a major role in calcium absorption<sup>72</sup> where calcium-binding protein is expressed and is specifically stimulated by FOS.<sup>7, 79, 80</sup> The mechanism is not clear, but increased solubility of calcium because of fermentation, which lowers caecal pH and increases SCFA production, or changes intracellular Ca<sup>2+</sup> concentration, which may enhance paracellular transport, are all possible.<sup>81–84</sup> The caecal microbiota may be involved, because the stimulatory effect of GOS on calcium absorption is suppressed by neomycin.<sup>85</sup> However, in humans it is not thought that the large bowel has a major role to play in calcium absorption, but it is reassuring to read that prebiotics also enhance this process, especially in adolescents and less certainly in young men and postmenopausal women. Table 4 summarizes eight studies from which it can be seen that both FOS and inulin increase calcium absorption, which in the 1 year investigation of Abrams *et al.*<sup>86</sup> led to a greater bone mineral density in the prebiotic group. In the two studies of young men, the results are conflicting, possibly because two different methods for measuring calcium absorption were used. The double isotope method of van den Heuvel *et al.*,<sup>87</sup> carried out at day 21 of the diet period, did not show a benefit of either inulin, FOS or GOS, despite a reasonable dose of prebiotic (15 g/day). The authors subsequently felt that the double isotope technique they used 'did not include the colonic component of calcium absorption...' because 24 h urine was used to calculate isotope enrichment, which would not allow long enough for a colonic phase to be detected. However, the double isotope technique has been used successfully in adolescents to demonstrate enhanced absorption, although urine collection in these studies was for 36 h<sup>88</sup> or 48 h.<sup>89</sup> Coudray *et al.*<sup>90</sup> used classical metabolic balance techniques to show increased absorption. Despite the belief that calcium absorption is thought to occur in the proximal gut in humans, a colonic phase may exist. Ellegard *et al.*<sup>91</sup> showed that neither inulin nor FOS when fed to ileostomy subjects had any effect on ileostomy excretion of calcium, magnesium, zinc or iron. As prebiotic carbohydrates pass through the small bowel unchanged, but are fermented in the caecum or colon, a large bowel effect on absorption is possible.

Prebiotics have also been reported to increase the uptake of other metal ions from the gut. Ducros *et al.*<sup>92</sup> reported that feeding 10 g of FOS per day for 5 weeks increased the absorption of copper in healthy postmenopausal women. In a randomized double-

blind, placebo-controlled trial, however, no effects were seen in relation to zinc and selenium uptake. This selectivity would suggest that factors other than simple acidification of luminal contents were involved.

Taken together, these studies give a strong indication that prebiotics can increase calcium absorption and bone mineral density. For the gastroenterologist, this could be a simple, harmless and beneficial adjunct to the management of bone problems in CD, coeliacs and postgastrectomy syndromes.

## OTHER TOPICS

The possible health benefits of prebiotics are now being explored in many situations, facilitated by their safety and ease of use. A substantial literature is accumulating on prebiotics and cancer, but much of the published work is in animals, where the role of prebiotics looks to be beneficial, whereas human studies are mostly concerned with identification of early biomarkers of risk.<sup>93</sup> Prebiotics are now being added to follow-on feeds for infants,<sup>94</sup> a practice which is riding on the back of clear benefits to children of probiotics in preventing and ameliorating the symptoms of acute infectious diarrhoea, and in atopic disease. Their use to prevent necrotizing enterocolitis shows promise in animal models.<sup>95</sup> Prebiotics clearly change the gut microbiota of infants and alter large bowel function, but large clinical trials are awaited. Another area of importance is lipid metabolism where prebiotic studies in animals have shown reduced blood levels of cholesterol and triglycerides and beneficial effects on fatty liver. Clinical trials in humans have not yielded such consistent results, although the effects on hepatic lipid metabolism are worth further study.<sup>96, 97</sup> There is also great interest in prebiotics in the pet food and animal feed industry,<sup>98</sup> where improved control of gastrointestinal infection is reported and enhanced growth performance is seen particularly in poultry. Other areas of interest include prebiotics and immunomodulation of the gut immune system, glycaemic control, behavioural effects, especially cognitive performance and the enhancement of probiotic activity in synbiotics.

## CONCLUSION

Prebiotics are short-chain carbohydrates (oligosaccharides) that have unusual effects in the gut. They alter the composition, or balance, of the microbiota, both in the lumen and at the mucosal surface, to one in which

bifidobacteria and lactobacilli come to greater prominence. This, so-called healthier flora, should provide increased resistance to gut infections and may also have immunomodulatory properties. Prebiotics also act as carbon and energy sources for bacteria growing in the large bowel, where they are fermented to SCFA and are energy sources for the gut and other body tissues. For regulatory purposes, the definition of 'prebiotic' needs to be clarified, particularly with respect to the concept of non-digestibility and the exact parameters that constitute selective modification of the gut microbiota.

In a clinical context, prebiotics are relatively poor laxatives and have been used without much success to manage constipation, whilst in the prevention of TD, a single study indicates a reduction of diarrhoea severity. There are no published RCT of prebiotics and IBS, and two RCT in the prevention of AAD made no impact on symptoms or risk, unlike probiotics, which are effective in this condition. Animal studies of prebiotics and IBD show benefits across a wide range of models, and with varying prebiotics, but again, there are no RCT in humans. One study of a synbiotic shows anti-inflammatory effects, while pouchitis may also improve. Perhaps surprisingly, a clear benefit of increased calcium absorption is seen and increased bone mineral density in adolescents with prebiotics.

It is still early days for prebiotics, but evidence increasingly suggests that they offer the potential to modify the gut microbial balance in such a way as to bring direct health benefits cheaply and safely.

## LITERATURE SEARCH STRATEGY

We have primarily used the Science Citation Index together with our own files on the subject, which go back to the 1980s, and direct searching for papers by key authors in the field, and of the EU ENDO project (DG XII AIR11 CT94-1095). Use of the search term 'prebiotic\*' alone is not helpful because it delivers many papers in organic chemistry which refer to the synthesis of compounds that existed before early life forms. It also turns up a number of papers on oligosaccharide chemistry. 'Prebiotic\*' was, therefore, combined for searches covering the years 1995–2006 with microbiota or microflora, gut bacteria, large intestine, fermentation, SCFA, ageing, mucosa, bowel habit, constipation, diarrhoea, inflammatory bowel disease, Crohn's disease, ulcerative colitis, pouchitis, calcium, cancer. Search of the Cochrane Library did

not identify any clinical studies of meta-analysis on this topic. We have focused in this review principally on studies in humans and reports in the English language.

## ACKNOWLEDGEMENT

Financial support provided by Chief Scientist Office, Scottish Executive.

## REFERENCES

- Gibson GR, Roberfroid M. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. *J Nutr* 1995; **125**: 1401–12.
- Gibson GR, Probert HM, Van Loo J, Rastall RA, Roberfroid M. Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. *Nutr Res Rev* 2004; **17**: 259–75.
- Roberfroid M. *Inulin-type Fructans. Functional Food Ingredients*. Boca Raton, Florida: CRC Press, 2005.
- Stephen AM, Cummings JH. Mechanism of action of dietary fibre in the human colon. *Nature* 1980; **284**: 283–4.
- Macfarlane GT, Cummings JH. The colonic flora, fermentation and large bowel digestive function. In: Phillips SF, Pemberton JH, Shorter RG, eds. *The Large Intestine: Physiology, Pathophysiology and Disease*. New York: Raven Press, 1991: 51–92.
- Cummings J, Kong SC. Probiotics, prebiotics and antibiotics in inflammatory bowel disease. In: Chadwick D, Goode J, eds. *Inflamm Bowel Dis*. Chichester: John Wiley & Sons, 2004: 99–114.
- Langlands SJ, Hopkins MJ, Coleman N, Cummings JH. Prebiotic carbohydrates modify the mucosa-associated microflora of the human large bowel. *Gut* 2004; **53**: 1610–6.
- Duncan SH, Scott KP, Ramsay AG, *et al.* Effects of alternative dietary substrates on competition between human colonic bacteria in an anaerobic fermentor system. *Appl Environ Microbiol* 2003; **69**: 1136–42.
- Macfarlane S, Macfarlane GT. Bacterial diversity in the large intestine. *Adv Appl Microbiol* 2004; **54**: 261–89.
- Cummings JH, Antoine J-M, Azpiroz F, *et al.* Gut health and immunity. *Eur J Nutr* 2004; **43**: II/118–73.
- Cummings JH, Macfarlane GT. The control and consequences of bacterial fermentation in the human colon. *J Appl Bacteriol* 1991; **70**: 443–59.
- Gibson GR, McCartney AL, Rastall RA. Prebiotics and resistance to gastrointestinal infections. *Br J Nutr* 2005; **93**: S31–4.
- Bartosch S, Woodmansey EJ, Paterson JCM, McMurdo MET, Macfarlane GT. Microbiological effects of consuming a synbiotic containing *Bifidobacterium bifidum*, *Bifidobacterium lactis* and oligofructose in elderly persons, determined by real-time polymerase chain reaction and counting of viable bacteria. *Clin Infect Dis* 2005; **40**: 28–37.
- Macfarlane S, Cummings JH, Macfarlane GT. Bacterial colonisation of surfaces in the large intestine. In: Gibson GR, Roberfroid M, eds. *Colonic Microflora, Nutrition and Health*. London: Chapman & Hall, 1999: 71–87.
- Macfarlane S, Hopkins MJ, Macfarlane GT. Bacterial growth and metabolism on surfaces in the large intestine. *Microb Ecol Health Dis* 2000; **2**: 64–72.
- Macfarlane S, Furrie E, Cummings JH, Macfarlane GT. Chemotaxonomic analysis of bacterial populations colonizing the rectal mucosa in patients with ulcerative colitis. *Clin Infect Dis* 2004; **38**: 1690–9.
- Lu L, Walker A. Pathologic and physiologic interactions of bacteria with the gastrointestinal epithelium. *Am J Clin Nutr* 2001; **73**: 1124S–30S.
- Furrie E, Macfarlane S, Kennedy A, *et al.* Synbiotic therapy (*Bifidobacterium longum*/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. *Gut* 2005; **54**: 242–9.
- Prindiville T, Cantrell M, Wilson K. Ribosomal DNA Sequence analysis of mucosa-associated bacteria in Crohn's disease. *Inflamm Bowel Dis* 2004; **10**: 824–33.
- Cummings JH, Macfarlane GT. Gastrointestinal effects of prebiotics. *Br J Nutr* 2002; **87**: S145–151.
- Rycroft CE, Jones MR, Gibson GR, Rastall RA. A comparative in vitro evaluation of the fermentation properties of probiotic oligosaccharides. *J Appl Microbiol* 2001; **91**: 878–87.
- Van Laere KMJ, Hartemink R, Bosveld M, Schols HA, Voragen AGJ. Fermentation of plant cell wall derived polysaccharides and their corresponding oligosaccharides by intestinal bacteria. *J Agric Food Chem* 2000; **48**: 1644–52.
- Ito M, Deguchi Y, Miyamori A, *et al.* Effects of administration of galactooligosaccharides on the human faecal microflora, stool weight and abdominal sensation. *Microb Ecol Health Dis* 1990; **3**: 285–92.
- Gibson GR, Beatty ER, Wang X, Cummings JH. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. *Gastroenterology* 1995; **108**: 975–82.
- Alles MS, Hautvast JGAJ, Nagengast FM, Hartemink R, Van Laere KMJ, Jansen JBMJ. Fate of fructo-oligosaccharides in the human intestine. *Br J Nutr* 1996; **76**: 211–21.
- Bouhnik Y, Flourié B, D'Agay-Abensour L, *et al.* Administration of transgalactooligosaccharides increases fecal bifidobacteria and modifies colonic fermentation metabolism in healthy humans. *J Nutr* 1997; **127**: 444–8.
- Castiglia-Delavaud C, Verdier E, Bessle JM, *et al.* Net energy value of non-starch polysaccharide isolates (sugarbeet fibre and commercial inulin) and their impact on nutrient digestive utilization in healthy human subjects. *Br J Nutr* 1998; **80**: 343–52.
- van Dokkum W, Wezendonk B, Sriksmar TS, van den Heuvel EGHM. Effect of nondigestible oligosaccharides on large-bowel functions, blood lipid concentrations and glucose absorption in young healthy male subjects. *Eur J Clin Nutr* 1999; **53**: 1–7.
- Gostner A, Schäffer V, Theis S, *et al.* Effects of isomalt consumption on gastrointestinal and metabolic parameters in healthy volunteers. *Br J Nutr* 2005; **94**: 575–81.
- Cummings JH. The effect of dietary fiber on fecal weight and composition. In: Spiller GA, ed. *CRC Handbook of Dietary Fiber in Human Nutrition*, 3rd



- edn. Tampa, Florida: CRC Press LLC, 2001: 183–252.
- 31 Van Loo J. The specificity of the interaction with intestinal bacterial fermentation by prebiotics determines their physiological efficacy. *Nutr Res Rev* 2004; 17: 89–98.
  - 32 Lewis HB. The value of inulin as a food-stuff. *J Am Med Assoc* 1912; LVIII: 1176–7.
  - 33 Hidaka H, Mirayama M. Useful characteristics and commercial applications of fructo-oligosaccharides. *Biochem Soc Trans* 1991; 19: 561–5.
  - 34 Kleessen B, Sykura B, Zunft H-J, Blaut M. Effects of inulin and lactose on fecal microflora, microbial activity, and bowel habit in elderly constipated persons. *Am J Clin Nutr* 1997; 65: 1397–402.
  - 35 Teuri U, Korpel R. Galacto-oligosaccharides relieve constipation in elderly people. *Ann Nutr Metab* 1998; 42: 319–27.
  - 36 Den Hond E, Geypens B, Ghooys Y. Effect of high performance chicory inulin on constipation. *Nutr Res* 2000; 20: 731–6.
  - 37 Chen H-L, Lu Y-H, Lin J-J, Ko L-Y. Effects of fructooligosaccharide on bowel function and indicators of nutritional status in constipated elderly men. *Nutr Res* 2000; 20: 1725–33.
  - 38 Chen H-L, Lu Y-H, Lin J-J, Ko L-Y. Effects of isomalto-oligosaccharides on bowel functions and indicators of nutritional status in constipated elderly men. *J Am Coll Nutr* 2001; 20: 44–9.
  - 39 Bouhnik Y, Neut C, Raskine L, et al. Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation. *Aliment Pharmacol Ther* 2004; 19: 889–99.
  - 40 Cummings JH, Christie S, Cole TJ. A study of fructo oligosaccharides in the prevention of travellers' diarrhoea. *Aliment Pharmacol Ther* 2001; 15: 1139–45.
  - 41 Azpiroz F. Intestinal perception: mechanisms and assessment. *Br J Nutr* 2005; 93: S7–S12.
  - 42 Smith AP. The concept of well-being: relevance to nutrition research. *Br J Nutr* 2005; 93: S1–S5.
  - 43 Hasler WL. Fecal flora in irritable bowel syndrome: characterization using molecular methods. *Gastroenterology* 2005; 129: 759–61.
  - 44 King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. *Lancet* 1998; 352: 1187–9.
  - 45 Dear KLE, Elia M, Hunter JO. Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome? *Dig Dis Sci* 2005; 50: 758–66.
  - 46 Serra J, Azpiroz A, Malagelada J-R. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. *Gut* 2001; 48: 14–9.
  - 47 Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. *Am J Gastroenterol* 2005; 100: 373–82.
  - 48 Macfarlane GT, Gibson GR. Carbohydrate fermentation, energy transduction and gas metabolism in the human large intestine. In: Mackie RI, White BA, eds. *Ecology and Physiology of Gastrointestinal Microbes, Vol. 1: Gastrointestinal Fermentations and Ecosystems*. New York: Chapman & Hall, 1996: 269–318.
  - 49 Stone-Dorshow T, Levitt MD. Gaseous response to ingestion of a poorly absorbed fructo-oligosaccharide sweetener. *Am J Clin Nutr* 1987; 46: 61–5.
  - 50 Hunter JO, Tuffnell Q, Lee AJ. Controlled trial of oligofructose in the management of irritable bowel syndrome. *J Nutr* 1999; 129: 1451S–3S.
  - 51 Hopkins MJ, Macfarlane GT. Nondigestible oligosaccharides enhance bacterial colonization resistance against *Clostridium difficile* in vitro. *Appl Environ Microbiol* 2003; 69: 1920–7.
  - 52 Lewis S, Burmeister S, Cohen S, Brazier J, Awasthi A. Failure of dietary oligofructose to prevent antibiotic-associated diarrhoea. *Aliment Pharmacol Ther* 2005; 21: 469–77.
  - 53 Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of *Clostridium difficile*-associated diarrhea: a randomized, controlled study. *Clin Gastroenterol Hepatol* 2005; 3: 442–8.
  - 54 Brunser O, Gotteland M, Cruchet S, Garrido D, Figueroa G, Steenhout P. Effect of an infant formula with prebiotics on the intestinal microbiota after an antibiotic treatment. *J Pediatr Gastroenterol Nutr* 2005; 40: 691–2.
  - 55 Rayes N, Seehofer D, Theruvath T, et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation – a randomized, double-blind trial. *Am J Transplant* 2005; 5: 125–30.
  - 56 Anderson ADG, McNaught CE, Jain PK, MacFie J. Randomised clinical trial of synbiotic therapy in elective surgical patients. *Gut* 2004; 53: 241–5.
  - 57 Hart AL, Kamm MA. Use of probiotics in the treatment of inflammatory bowel disease. *J Clin Gastroenterol* 2003; 36: 111–9.
  - 58 Kruis W, Frick P, Paokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic *Escherichia coli* Nissle 1917 is as effective as with standard mesalazine. *Gut* 2004; 53: 1617–23.
  - 59 Cherbut C, Michel C, Lecannu G. The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats. *J Nutr* 2003; 133: 21–7.
  - 60 Camuesco D, Peran L, Comalada M, et al. Preventative effects of lactulose in the trinitrobenzenesulphonic acid model of rat colitis. *Inflamm Bowel Dis* 2005; 11: 265–71.
  - 61 Videla S, Vilaseca J, Antolin M, et al. Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. *Am J Gastroenterol* 2001; 96: 1486–93.
  - 62 Moreau NM, Martin LJ, Toquet CS, et al. Restoration of the integrity of rat caecocolonic mucosa by resistant starch, but not by fructo-oligosaccharides, in dextran sulfate sodium-induced experimental colitis. *Br J Nutr* 2003; 90: 75–85.
  - 63 Rumi G, Tsubouchi R, Okayama M, Kato S, Mozsik G, Takeuchi K. Protective effect of lactulose on dextran sulfate sodium-induced colonic inflammation in rats. *Dig Dis Sci* 2004; 49: 1466–72.
  - 64 Hoentjen F, Welling GW, Harmsen HJM, et al. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. *Inflamm Bowel Dis* 2005; 11: 977–85.
  - 65 Hanai H, Kanauchi O, Mitsuyama K, et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. *Int J Mol Med* 2004; 13: 643–7.
  - 66 Lindsay JO, Whelan K, Stagg AJ, et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. *Gut* 2006; 55: 348–55.
  - 67 Welters CFM, Heineman E, Thunnissen BJM, van den Bogaard AEJM, Soeters PB, Baeten CGMI. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. *Dis Colon Rectum* 2002; 45: 621–7.
  - 68 Zitterman A, Bock P, Drummer C, Scheld K, Heer M, Stehle P. Lactose does



- not enhance calcium bioavailability in lactose-tolerant, healthy adults. *Am J Clin Nutr* 2000; **71**: 931–6.
- 69 Ohta A, Ohtsuki M, Baba S, Adachi T, Sakata T, Sakaguchi E. Calcium and magnesium absorption from the colon and rectum are increased in rats fed fructooligosaccharides. *J Nutr* 1995; **125**: 2417–24.
- 70 Ohta A, Ohtsuki M, Baba S, Takizawa T, Adachi T, Kimura S. Effects of fructooligosaccharides on the absorption of iron, calcium and magnesium in iron-deficient anemic rats. *J Nutr Sci Vitaminol (Tokyo)* 1995; **41**: 281–91.
- 71 Motohashi T, Sano T, Ohta A, Yamada S. True calcium absorption in the intestine is enhanced by fructooligosaccharides feeding in rats. *J Nutr* 1998; **128**: 1815–8.
- 72 Chonan O, Watanuki M. Effect of galactooligosaccharides on calcium-absorption in rats. *J Nutr Sci Vitaminol (Tokyo)* 1995; **41**: 95–104.
- 73 Younes H, Coudray C, Bellanger J, Demingné C, Rayssiguier Y, Rémésy C. Effects of two fermentable carbohydrates (inulin and resistant starch) and their combination on calcium and magnesium balance in rats. *Br J Nutr* 2001; **86**: 479–85.
- 74 Delzenne N, Aertssens J, Verplaetse H, Roccaro M, Roberfroid M. Effect of fermentable fructo-oligosaccharides on mineral, nitrogen and energy digestive balance in the rat. *Life Sci* 1995; **57**: 1579–87.
- 75 Chonan O, Watanuki M. The effect of 6'-galactooligosaccharides on bone mineralization of rats adapted to different levels of dietary calcium. *Int J Vitam Nutr Res* 1996; **66**: 244–9.
- 76 Ohta A, Ohtsuki M, Uehara M, *et al.* Dietary fructooligosaccharides prevent postgastrectomy anemia and osteopenia in rats. *J Nutr* 1998; **128**: 485–90.
- 77 Scholz-Ahrens KE, Acil Y, Schrezenmeir J. Effect of oligofructose or dietary calcium on repeated calcium and phosphorus balances, bone mineralization and trabecular structure in ovariectomized rats. *Br J Nutr* 2002; **88**: 365–77.
- 78 Civitelli R, Avioli LV. Calcium, phosphate, and magnesium absorption. In: Johnson LR, Alpers DH, Christensen J, Jacobson ED, Walsh JH, eds. *Physiology of the Gastrointestinal Tract*, Vol. 2, 3rd edn. New York: Raven Press, 1994: 2173–81.
- 79 Ohta A, Motohashi Y, Sakai K, Hirayama M, Adachi T, Sakuma K. Dietary fructooligosaccharides increase calcium absorption and levels of mucosal calbindin-D9k in the large intestine of gastrectomized rats. *Scand J Gastroenterol* 1998; **33**: 1062–8.
- 80 Ohta A, Motohashi Y, Ohtsuki M, Hirayama M, Adachi T, Sakuma K. Dietary fructooligosaccharides change the concentration of calbindin-D9k differently in the mucosa of the small and large intestine of rats. *J Nutr* 1998; **128**: 934–9.
- 81 Suzuki T, Hara H. Various non-digestible saccharides increase intracellular calcium ion concentration in rat small-intestinal enterocytes. *Br J Nutr* 2004; **92**: 751–5.
- 82 Chonan O, Matsumoto K, Watanuki M. Effect of galactooligosaccharides on calcium-absorption and preventing bone loss in ovariectomized rats. *Biosci Biotechnol Biochem* 1995; **59**: 236–9.
- 83 Remesy C, Levrat MA, Gamet L, Demigne C. Cecal fermentations in rats fed oligosaccharides (inulin) are modulated by dietary calcium level. *Am J Physiol* 1993; **264**: G855–62.
- 84 Scholz-Ahrens KE, Schrezenmeir J. Inulin, oligofructose and mineral metabolism – experimental data and mechanism. *Br J Nutr* 2002; **87**: S179–86.
- 85 Chonan O, Takahashi R, Watanuki M. Role of activity of gastrointestinal microflora in absorption of calcium and magnesium in rats fed beta 1–4 linked galactooligosaccharides. *Biosci Biotechnol Biochem* 2001; **65**: 1872–5.
- 86 Abrams SA, Griffin IJ, Hawthorne KM, *et al.* A combination of prebiotic short- and long-chain inulin-type fructans enhances calcium absorption and bone mineralization in young adolescents. *Am J Clin Nutr* 2005; **82**: 471–6.
- 87 van den Heuvel EGHM, Schaafsma G, Muys T, van Dokkum W. Nondigestible oligosaccharides do not interfere with calcium an nonheme-iron absorption in young, healthy men. *Am J Clin Nutr* 1998; **67**: 445–51.
- 88 van den Heuvel EGHM, Muys T, van Dokkum M, Schaafsma G. Oligofructose stimulates calcium absorption in adolescents. *Am J Clin Nutr* 1999; **69**: 544–8.
- 89 Griffin IJ, Davila PM, Abrams SA. Nondigestible oligosaccharides and calcium absorption in girls with adequate calcium intakes. *Br J Nutr* 2002; **87**: S187–91.
- 90 Coudray C, Bellanger J, Castiglia-Delavaud C, Remesy C, Vermorel M, Raysiguier Y. Effect of soluble or partly soluble dietary fibres supplementation on absorption and balance of calcium, magnesium, iron and zinc in healthy young men. *Eur J Clin Nutr* 1997; **51**: 365–80.
- 91 Ellegard L, Andersson H, Bosaeus I. Inulin and oligofructose do not influence the absorption of cholesterol, or the excretion of cholesterol, Ca, Mg, Zn, Fe, or bile acids but increases energy excretion in ileostomy subjects. *Eur J Clin Nutr* 1997; **51**: 1–5.
- 92 Ducros V, Arnaud J, Tahiri M, *et al.* Influence of short-chain fructo-oligosaccharides (sc-FOS) on absorption of Cu, Zn, and Se in healthy post-menopausal women. *J Am Coll Nutr* 2005; **24**: 30–7.
- 93 Pool-Zobel BL. Inulin-type fructans and reduction in colon cancer risk: a review of experimental and human data. *Br J Nutr* 2005; **93**: S73–90.
- 94 Fanaro S, Boehm G, Garssen J, *et al.* Galacto-oligosaccharides and long-chain fructo-oligosaccharides as prebiotics in infant formulas: a review. *Acta Paediatr* 2005; **94**: 22–6.
- 95 Butel M-J, Waligora-Dupriet A-J, Szylit O. Oligofructose and experimental model of neonatal necrotising enterocolitis. *Br J Nutr* 2002; **87**: S213–9.
- 96 Williams CM, Jackson KG. Inulin and oligofructose: effects on lipid metabolism from human studies. *Br J Nutr* 2002; **87**: S261–4.
- 97 Beylot M. Effects of inulin-type fructans on lipid metabolism in man and in animal models. *Br J Nutr* 2005; **93**: S163–8.
- 98 Flickinger EA, Fahey GC Jr. Pet food and feed applications of inulin, oligofructose and other oligosaccharides. *Br J Nutr* 2002; **87**: S297–300.
- 99 Tahiri M, Tressol JC, Arnaud J, *et al.* Effect of short-chain fructooligosaccharides on intestinal calcium absorption and calcium status in postmenopausal women: a stable-isotope study. *Am J Clin Nutr* 2003; **77**: 449–57.
- 100 van den Heuvel EGHM, Schoterman MHC, Muijs T. Transgalactooligosaccharides stimulate calcium absorption in postmenopausal women. *J Nutr* 2000; **130**: 2938–42.
- 101 López-Huertas E, Teucher B, Boza JJ, *et al.* Absorption of calcium from milks enriched with fructo-oligosaccharides, caseinophosphopeptides, tricalcium phosphate, and milk solids. *Am J Clin Nutr* 2006; **83**: 310–6.